"We welcome Michael as an instrumental addition to our Supervisory Board," said Hans Schikan, Prosensa's CEO. "Michael's extensive financial and transactional expertise will support the company significantly in our efforts to bring much-needed, life-saving treatments for rare genetic diseases to patients. His long-term tenure at Genzyme, one of the most successful companies in the rare disease space, will be invaluable as we continue developing therapies for boys with Duchenne muscular dystrophy and building our company."
"Michael's corporate leadership experience in
rare diseases makes him an ideal fit for Prosensa, and his
contribution will be vital as the company works to successfully
advance its DMD drug pipeline," said
"I am pleased to join Prosensa at such a
significant moment in the company's history and look forward to
working alongside a world-class team with exceptional leadership in
rare diseases," said
Notes to editors
About Prosensa Holding N.V.
Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington's disease.
Prosensa's current portfolio includes six compounds for the
treatment of DMD, all of which have received orphan drug status in
CONTACT: Prosensa Holding N.V.
Celia Economides, Senior Director, IR & Corporate CommunicationsPhone: +1 917 941 9059 Email: email@example.com
News Provided by Acquire Media